Direct antibiotic resistance breakers (or ARBs) have been known within the human and animal antimicrobial market for some time (for example, beta-lactamase inhibitors). The problem with new antibiotics and direct ARBs are that they encourage new resistance to form and are often only compatible with a limited range of bacterial strains or antibiotics. And so the cycle continues.

 

NeoX™ includes a proprietary, non-antibiotic, small molecule that causes rapid collapse of mature biofilms and sensitizes bacteria to accessible, affordable existing therapies. Promising results to date suggest that NeoX™ is broadly applicable across bacterial species and antibiotic classes.

 

The lead development candidate, NeoX-101, is in preparation to enter clinical development in 2024 as an inhaled therapy for respiratory infections.